



## Clinical trial results:

**A multicentre, double-blind, placebo-controlled, randomized trial to assess the efficacy and tolerability of two dosing regimens of AllerT, a combination of contiguous overlapping peptides derived from Bet v 1, in adult subjects allergic to birch pollen**

### Summary

|                          |                |
|--------------------------|----------------|
| EudraCT number           | 2011-002259-32 |
| Trial protocol           | SE LT DK LV    |
| Global end of trial date | 30 June 2013   |

### Results information

|                                   |   |
|-----------------------------------|---|
| Result version number             | v1 (current)  |
| This version publication date     | 01 January 2020                                     |
| First version publication date    | 01 January 2020                                     |
| Summary attachment (see zip file) | AN004T RESULTS SUMMARY (AN004T EUDRACT RESULTS.pdf) |

### Trial information

#### Trial identification

|                       |        |
|-----------------------|--------|
| Sponsor protocol code | AN004T |
|-----------------------|--------|

#### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT01720251 |
| WHO universal trial number (UTN)   | -           |

Notes:

### Sponsors

|                              |  |
|------------------------------|--|
| Sponsor organisation name    | Anergis SA   |
| Sponsor organisation address | Route de la Corniche 4, EPALINGES, Switzerland, 1066                   |
| Public contact               | Vincent Charlon, Anergis SA, +41 216519220, vincent.charlon@anergis.ch |
| Scientific contact           | Vincent Charlon, Anergis SA, +41 216519220, vincent.charlon@anergis.ch |

Notes:

### Paediatric regulatory details

|  |    |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

---

**Results analysis stage**

---

|  |               |
|--|---------------|
| Analysis stage                                       | Final         |
| Date of interim/final analysis                       | 31 March 2014 |
| Is this the analysis of the primary completion data? | Yes           |
| Primary completion date                              | 14 June 2013  |
| Global end of trial reached?                         | Yes           |
| Global end of trial date                             | 30 June 2013  |
| Was the trial ended prematurely?                     | No            |

Notes:

---

**General information about the trial**

---

Main objective of the trial:

To demonstrate the efficacy of a two months pre-seasonal treatment with AllerT 100 µg maintenance dose in reducing symptoms of allergic rhinoconjunctivitis during the following birch pollen season

Protection of trial subjects:

N/A

Background therapy: -

Evidence for comparator: -

|   |                 |
|---|-----------------|
| Actual start date of recruitment                          | 01 October 2012 |
| Long term follow-up planned                               | No              |
| Independent data monitoring committee (IDMC) involvement? | No              |

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

|                                      |                |
|--------------------------------------|----------------|
| Country: Number of subjects enrolled | Poland: 86     |
| Country: Number of subjects enrolled | Sweden: 33     |
| Country: Number of subjects enrolled | Denmark: 46    |
| Country: Number of subjects enrolled | France: 13     |
| Country: Number of subjects enrolled | Latvia: 39     |
| Country: Number of subjects enrolled | Lithuania: 21  |
| Country: Number of subjects enrolled | Switzerland: 2 |
| Worldwide total number of subjects   | 240            |
| EEA total number of subjects         | 238            |

Notes:

---

**Subjects enrolled per age group**

---

|   |   |
|---|---|
| In utero                                  | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days)                      | 0 |
| Infants and toddlers (28 days-23 months)  | 0 |
| Children (2-11 years)                     | 0 |
| Adolescents (12-17 years)                 | 0 |

|                      |     |
|----------------------|-----|
| Adults (18-64 years) | 240 |
| From 65 to 84 years  | 0   |
| 85 years and over    | 0   |

## Subject disposition

### Recruitment

Recruitment details:

Man or woman aged 18 to 55 years

- Presenting moderate to severe allergic rhinoconjunctivitis to birch pollen confirmed at screening by meeting all of the following criteria:
  - An RSS 12 for the 2 preceding birch pollen seasons based on subject's interview by the investigator
  - Previous use of anti-allergy medication during the 2 preceding b

### Pre-assignment

Screening details:

Man or woman aged 18 to 55 years

- Presenting moderate to severe allergic rhinoconjunctivitis to birch pollen confirmed at screening by meeting all of the following criteria:
  - An RSS 12 for the 2 preceding birch pollen seasons based on subject's interview by the investigator
  - Previous use of anti-allergy medication during the 2 preceding b

### Pre-assignment period milestones

|                              |     |
|------------------------------|-----|
| Number of subjects started   | 240 |
| Number of subjects completed | 240 |

### Period 1

|                              |  |
|------------------------------|--|
| Period 1 title               | overall trial (overall period)               |
| Is this the baseline period? | Yes  |
| Allocation method            | Randomised - controlled                      |
| Blinding used                | Double blind                                 |
| Roles blinded                | Subject, Investigator, Monitor, Data analyst |

### Arms

|                              |            |
|------------------------------|------------|
| Are arms mutually exclusive? | Yes        |
| <b>Arm title</b>             | AllerT 100 |

Arm description:

AllerT 100 ug target dose

|  |                  |
|--|------------------|
| Arm type                               | Experimental     |
| Investigational medicinal product name | AllerT           |
| Investigational medicinal product code |                  |
| Other name                             |                  |
| Pharmaceutical forms                   | Injection        |
| Routes of administration               | Subcutaneous use |

Dosage and administration details:

5 injections on days 1, 7, 14, 28, 56

Target doses: half dose on Day 1 and full dose on days 7, 14, 28, 56 unless adjusted due to adverse events

|                          |              |
|--------------------------|--------------|
| <b>Arm title</b>         | AllerT 50 ug |
| Arm description:         |              |
| AllerT target dose 50 ug |              |
| Arm type                 | Experimental |

|  |                  |
|--|------------------|
| Investigational medicinal product name | AllerT           |
| Investigational medicinal product code |                  |
| Other name                             |                  |
| Pharmaceutical forms                   | Injection        |
| Routes of administration               | Subcutaneous use |

Dosage and administration details:

5 injections on days 1, 7, 14, 28, 56

Target doses: half dose on Day 1 and full dose on days 7, 14. 28. 56 unless adjusted due to adverse events

|                  |         |
|------------------|---------|
| <b>Arm title</b> | placebo |
|------------------|---------|

Arm description:

placebo control

|  |                         |
|--|-------------------------|
| Arm type                               | Placebo                 |
| Investigational medicinal product name | placebo with alhydrogel |
| Investigational medicinal product code |                         |
| Other name                             |                         |
| Pharmaceutical forms                   | Injection               |
| Routes of administration               | Subcutaneous use        |

Dosage and administration details:

placebo containing alhydrogel

| <b>Number of subjects in period 1</b> | AllerT 100 | AllerT 50 ug | placebo |
|---------------------------------------|------------|--------------|---------|
| Started                               | 82         | 79           | 79      |
| Completed                             | 82         | 79           | 79      |

## Baseline characteristics

### Reporting groups

|                              |              |
|------------------------------|--------------|
| Reporting group title        | AllerT 100   |
| Reporting group description: |              |
| AllerT 100 ug target dose    |              |
| Reporting group title        | AllerT 50 ug |
| Reporting group description: |              |
| AllerT target dose 50 ug     |              |
| Reporting group title        | placebo      |
| Reporting group description: |              |
| placebo control              |              |

| Reporting group values                             | AllerT 100 | AllerT 50 ug | placebo  |
|--|------------|--------------|----------|
| Number of subjects                                 | 82         | 79           | 79       |
| Age categorical                                    |            |              |          |
| Units: Subjects                                    |            |              |          |
| In utero   | 0          | 0            | 0        |
| Preterm newborn infants (gestational age < 37 wks) | 0          | 0            | 0        |
| Newborns (0-27 days)                               | 0          | 0            | 0        |
| Infants and toddlers (28 days-23 months)           | 0          | 0            | 0        |
| Children (2-11 years)                              | 0          | 0            | 0        |
| Adolescents (12-17 years)                          | 0          | 0            | 0        |
| Adults (18-64 years)                               | 82         | 79           | 79       |
| From 65-84 years                                   | 0          | 0            | 0        |
| 85 years and over                                  | 0          | 0            | 0        |
| Age continuous                                     |            |              |          |
| Units: years                                       |            |              |          |
| median   | 36.5       | 37.5         | 33       |
| full range (min-max)                               | 29 to 44   | 28 to 44     | 27 to 39 |
| Gender categorical                                 |            |              |          |
| Units: Subjects                                    |            |              |          |
| Female   | 43         | 36           | 41       |
| Male   | 39         | 43           | 38       |

| Reporting group values                             | Total |  |  |
|--|-------|--|--|
| Number of subjects                                 | 240   |  |  |
| Age categorical                                    |       |  |  |
| Units: Subjects                                    |       |  |  |
| In utero   | 0     |  |  |
| Preterm newborn infants (gestational age < 37 wks) | 0     |  |  |
| Newborns (0-27 days)                               | 0     |  |  |
| Infants and toddlers (28 days-23 months)           | 0     |  |  |
| Children (2-11 years)                              | 0     |  |  |
| Adolescents (12-17 years)                          | 0     |  |  |
| Adults (18-64 years)                               | 240   |  |  |

|                   |   |  |  |
|-------------------|---|--|--|
| From 65-84 years  | 0 |  |  |
| 85 years and over | 0 |  |  |

|                      |     |  |  |
|----------------------|-----|--|--|
| Age continuous       |     |  |  |
| Units: years         |     |  |  |
| median               |     |  |  |
| full range (min-max) | -   |  |  |
| Gender categorical   |     |  |  |
| Units: Subjects      |     |  |  |
| Female               | 120 |  |  |
| Male                 | 120 |  |  |

## End points

### End points reporting groups

|   |              |
|---|--------------|
| Reporting group title                                     | AllerT 100   |
| Reporting group description:<br>AllerT 100 ug target dose |              |
| Reporting group title                                     | AllerT 50 ug |
| Reporting group description:<br>AllerT target dose 50 ug  |              |
| Reporting group title                                     | placebo      |
| Reporting group description:<br>placebo control           |              |

### Primary: CSMS

|  |         |
|--|---------|
| End point title  | CSMS    |
| End point description:   |         |
| End point type   | Primary |
| End point timeframe:<br>daily combined symptom and medication score measured daily during the birch pollen season and averaged during the season defined on pollen counts in the air |         |

| End point values                        | AllerT 100      | AllerT 50 ug    | placebo         |  |
|---|-----------------|-----------------|-----------------|--|
| Subject group type                      | Reporting group | Reporting group | Reporting group |  |
| Number of subjects analysed             | 70              | 70              | 71              |  |
| Units: score                            |                 |                 |                 |  |
| least squares mean (standard deviation) | 0.73 (± 0.583)  | 0.63 (± 0.512)  | 0.87 (± 0.616)  |  |

### Statistical analyses

|   |                                     |
|---|-------------------------------------|
| Statistical analysis title              | modified ITT                        |
| Comparison groups                       | AllerT 100 v AllerT 50 ug v placebo |
| Number of subjects included in analysis | 211                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           | superiority                         |
| P-value                                 | < 0.05                              |
| Method                                  | ANCOVA                              |
| Parameter estimate                      | Mean difference (final values)      |



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

treatment period up until 4 weeks later or till the last visit of the trial 2-4 weeks after the end of the birch pollen season

|                 |                |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |    |
|--------------------|----|
| Dictionary version | 15 |
|--------------------|----|

### Reporting groups

|                       |         |
|-----------------------|---------|
| Reporting group title | placebo |
|-----------------------|---------|

Reporting group description: -

|                       |       |
|-----------------------|-------|
| Reporting group title | 50 ug |
|-----------------------|-------|

Reporting group description:

patients treated with AllerT 50 ug target dose group

|                       |        |
|-----------------------|--------|
| Reporting group title | 100 ug |
|-----------------------|--------|

Reporting group description:

patients treated with AllerT 100 ug target dose group

| Serious adverse events                            | placebo                                   | 50 ug          | 100 ug         |
|---|---|----------------|----------------|
| Total subjects affected by serious adverse events |   |                |                |
| subjects affected / exposed                       | 0 / 79 (0.00%)                            | 1 / 78 (1.28%) | 2 / 82 (2.44%) |
| number of deaths (all causes)                     | 0   | 0              | 0              |
| number of deaths resulting from adverse events    |   |                |                |
| Injury, poisoning and procedural complications    |   |                |                |
| Skull fracture                                    |   |                |                |
| subjects affected / exposed                       | 0 / 79 (0.00%)                            | 0 / 78 (0.00%) | 1 / 82 (1.22%) |
| occurrences causally related to treatment / all   | 0 / 0                                     | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all        | 0 / 0                                     | 0 / 0          | 0 / 0          |
| Immune system disorders                           |   |                |                |
| Hypersensitivity                                  | Additional description: allergic reaction |                |                |
| subjects affected / exposed                       | 0 / 79 (0.00%)                            | 1 / 78 (1.28%) | 1 / 82 (1.22%) |
| occurrences causally related to treatment / all   | 0 / 0                                     | 1 / 1          | 1 / 1          |
| deaths causally related to treatment / all        | 0 / 0                                     | 0 / 0          | 0 / 0          |

Frequency threshold for reporting non-serious adverse events: 1 %

| <b>Non-serious adverse events</b>                     | placebo          | 50 ug            | 100 ug           |
|---|------------------|------------------|------------------|
| Total subjects affected by non-serious adverse events |                  |                  |                  |
| subjects affected / exposed                           | 59 / 79 (74.68%) | 70 / 78 (89.74%) | 70 / 82 (85.37%) |
| General disorders and administration site conditions  |                  |                  |                  |
| Injection site reaction                               |                  |                  |                  |
| subjects affected / exposed                           | 53 / 79 (67.09%) | 53 / 78 (67.95%) | 51 / 82 (62.20%) |
| occurrences (all)                                     | 79               | 93               | 94               |
| Respiratory, thoracic and mediastinal disorders       |                  |                  |                  |
| Respiratory disorder                                  |                  |                  |                  |
| subjects affected / exposed                           | 15 / 79 (18.99%) | 39 / 78 (50.00%) | 47 / 82 (57.32%) |
| occurrences (all)                                     | 18               | 62               | 88               |
| Skin and subcutaneous tissue disorders                |                  |                  |                  |
| Pruritus  |                  |                  |                  |
| subjects affected / exposed                           | 3 / 79 (3.80%)   | 20 / 78 (25.64%) | 11 / 82 (13.41%) |
| occurrences (all)                                     | 3                | 30               | 19               |
| Infections and infestations                           |                  |                  |                  |
| Rhinitis  |                  |                  |                  |
| subjects affected / exposed                           | 7 / 79 (8.86%)   | 22 / 78 (28.21%) | 25 / 82 (30.49%) |
| occurrences (all)                                     | 8                | 45               | 54               |
| Nasopharyngitis                                       |                  |                  |                  |
| subjects affected / exposed                           | 14 / 79 (17.72%) | 13 / 78 (16.67%) | 16 / 82 (19.51%) |
| occurrences (all)                                     | 15               | 16               | 19               |

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported